Robotic Retroperitoneal Lymph Node Dissection for Lymphadenopathy Retroperitoneal

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Princess Margaret Cancer Centre, Toronto, Canada
Lymphadenopathy Retroperitoneal+3 More
Robotic Retroperitoneal Lymph Node Dissection (RPLND) - Procedure
Eligibility
18+
Male
What conditions do you have?
Select

Study Summary

This study will investigate the safety and efficacy of using robotic retroperitoneal lymph node dissection (R-RPLND), a minimally invasive surgical approach, as the first-line of treatment for stage IIA/B (or equivalent) seminoma patients. R-RPLND will be trialed as an alternative to chemotherapy, radiation therapy (for seminoma patients) and open RPLND in this study.

Eligible Conditions

  • Lymphadenopathy Retroperitoneal
  • stage II Testicular seminoma (pure)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 24 Secondary · Reporting Duration: 5 years after RPLND

4 months post-operatively
Quality of Life Surveys for Cancer Patients
Quality of Life Surveys for Testicular Cancer Patients
5 years after RPLND
Relapse Free Survival (RFS)
Hour 8
Conversion rate to open surgery
Estimated blood loss
Number of hemostatic agents
Number of lymph nodes resected
Operative time
Transfusion rate
Type of hemostatic agents
Day 2
Length of stay
Study duration (5 years)
Cancer-specific survival (CSS)
Complications
IGCCCG risk classification
Mode of relapse detection
Overall survival (OS)
Percentage of patients that are able to avoid adjuvant treatment
Rate of ejaculation
Rate of relapse
Relapse in vs. out of surgical field
Relapse tumour characteristics
Return to work
Time of return of ejaculation
Time to progression (TTP)
Treatment burden

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Robotic Retroperitoneal Lymph Node Dissection
1 of 1
Experimental Treatment

25 Total Participants · 1 Treatment Group

Primary Treatment: Robotic Retroperitoneal Lymph Node Dissection · No Placebo Group · N/A

Robotic Retroperitoneal Lymph Node Dissection
Procedure
Experimental Group · 1 Intervention: Robotic Retroperitoneal Lymph Node Dissection (RPLND) · Intervention Types: Procedure

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years after rplnd
Closest Location: Princess Margaret Cancer Centre · Toronto, Canada
Photo of princess margaret cancer centre  1Photo of princess margaret cancer centre  2Photo of princess margaret cancer centre  3
2021First Recorded Clinical Trial
1 TrialsResearching Lymphadenopathy Retroperitoneal
176 CompletedClinical Trials

Eligibility Criteria

Age 18+ · Male Participants · 9 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Patients with serum tumour marker elevation are eligible if the elevated marker does not exceed the following cut-offs within 10 days of RPLND: AFP (< 2.
You are under the care of a uro-oncologist at Princess Margaret Cancer Centre.
You have a histologically confirmed seminomatous testicular germ cell tumour with negative margins on radical orchiectomy.
The patient must have lymphadenopathy in the retroperitoneum (in the transverse plane) detected on contrast CT scan or MRI (CS IIA/B; or active surveillance relapse with CS IIA/B equivalent).
You have no evidence of metastasis in your chest.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.